Jacques Izopet

THETA: a new genotypic approach for predicting HIV-1 CRF02-AG coreceptor usage

Christelle Reynes, Chloé Dimeglio, Stéphanie Raymond, 2019, Bioinform..

Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients

Philippe Flandre, Vincent Calvez, Jacques Izopet, 2008, Antimicrobial Agents and Chemotherapy.

Kinetics of anti-ZIKV antibodies after Zika infection using two commercial enzyme-linked immunoassays.

Christophe Pasquier, Jacques Izopet, C. Mengelle, 2018, Diagnostic microbiology and infectious disease.

Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological Failure

Florence Nicot, Jacques Izopet, Jean-Pierre Aboulker, 2011, PloS one.

Population-Based Sequencing of the V3 Region of env for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 Quasispecies

Christophe Pasquier, Michelle Cazabat, Jacques Izopet, 2007, Journal of Clinical Microbiology.

HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial

Steve Kaye, Francoise Brun-Vezinet, Rob Schuurman, 1997, The Lancet.

R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy

Christophe Pasquier, Michelle Cazabat, Jacques Izopet, 2005, Journal of acquired immune deficiency syndromes.

Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy

Jacques Izopet, Diane Descamps, F. Brun-Vézinet, 2001, Journal of Virology.

European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay

Jordi Vila, Patrick Braun, Rafael Delgado, 2017, Journal of Clinical Microbiology.